Navigation Links
Receptos to Present at the Cowen and Company 32nd Annual Health Care Conference

SAN DIEGO, March 1, 2012 /PRNewswire/ -- Receptos Inc. today announced that the company is scheduled to present at the Cowen and Company 32nd Annual Health Care Conference at noon EST on Wednesday, March 7, 2012, at the Boston Marriott Copley Place in Boston, Massachusetts. Faheem Hasnain, president and chief executive officer, will provide an overview of the company and an update about its clinical development programs.

"This is an exciting time at Receptos as we move forward with plans to initiate multiple Phase 2 clinical trials later this year and to close our Series B financing round," Hasnain said. "This presentation at the Cowen and Company Health Care Conference gives us the opportunity to provide an update about these initiatives, as well as other areas of focus for Receptos."

About RPC1063 and S1P1 Agonists
RPC1063, developed in the labs of Receptos, is a novel, highly selective S1P1 agonist exhibiting picomolar potency that is effective in rodent models of multiple sclerosis, and possesses an excellent safety profile in non-clinical toxicology studies. In addition to selectivity, which reduces the likelihood of "off-target" side effects, RPC1063 has an appropriately short half-life to promote rapid reversibility of lymphopenia. S1P1 is a G protein-coupled receptor (GPCR) that binds the lipid signaling molecule sphingosine 1-phosphate (S1P). S1P is a circulating lipid that binds to five GPCRs termed S1P1-5. S1P1 selectively regulates physiological functions in the immune and cardiovascular systems, including immune cell trafficking and the maintenance of endothelial integrity. In the disease state of multiple sclerosis, S1P1 agonism works by selectively sequestering circulating lymphocytes, blunting the underlying autoimmune cause of multiple sclerosis.

About Receptos
Receptos is a biopharmaceutical company developing autoimmune therapeutic candidates through information‐driven drug discovery, including GPCR structure determination. The company's lead program is a best‐in‐class S1P1 small molecule agonist candidate for autoimmune indications, including multiple sclerosis and inflammatory bowel disease, which will complete a Phase 1 clinical study in the first quarter of 2012. The S1P1 program is supported by the company's proprietary high resolution protein crystal structure of the S1P1 receptor. Receptos has established partnerships for its GPCR structure determination technology platform with Eli Lilly, Ono Pharmaceutical and Janssen Pharmaceuticals, Inc. For more information visit

Media and Investor Contacts:
Russo Partners
Ian Stone or David Schull (media)
(619) 308-6541 or (212) 845-4271

Cindy McGee (investors)
(619) 308-6538

SOURCE Receptos Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Receptos Scientists Publish Determination of a High Resolution Sphingosine 1-Phosphate Receptor 1 Structure in Science
2. Receptos and Ono Establish Collaboration with Focus on Bioactive Lipid Discovery Research
3. Incline Therapeutics to Present at the Cowen and Company 32nd Annual Health Care Conference
4. Enox Biopharma, Inc. Will Present at IN360 Investment in Innovation Conference
5. BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March
6. Regeneron Announces March 2012 Investor Conference Presentations
7. Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA
8. OncoSec to Present at 10th Annual BioPartnering North America
9. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
10. Onyx Pharmaceuticals to Present at Upcoming Investor Conferences
11. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
Post Your Comments:
(Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
(Date:11/25/2015)... November 25, 2015 The ... is a professional and in-depth study on the ...      (Logo: ) , ... industry including definitions, classifications, applications and industry chain ... the international markets including development trends, competitive landscape ...
(Date:11/24/2015)... ... 24, 2015 , ... The United States Golf Association (USGA) today announced Dr. ... Award. Presented annually since 1961, the USGA Green Section Award recognizes an individual’s distinguished ... , Clarke, of Iselin, N.J., is an extension specialist of turfgrass pathology in ...
(Date:11/24/2015)... Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" or ... financial results for the quarter ended September 30, ... Canadian dollars and presented under International Financial Reporting ... ," said Andrew Rae , President ... iCo-008 are not only value enriching for this ...
Breaking Biology Technology:
(Date:11/17/2015)... Nov. 17, 2015 Pressure BioSciences, Inc. (OTCQB: ... development and sale of broadly enabling, pressure cycling technology ... industry, today announced it has received gross proceeds of ... Private Placement (the "Offering"), increasing the total amount raised ... more additional closings are expected in the near future. ...
(Date:11/11/2015)... Minn. , Nov. 11, 2015   MedNet Solutions ... entire spectrum of clinical research, is pleased to announce that ... in Clinical Trials (PCT) event, to be held November ... be able to view live demonstrations of iMedNet ... and learn how iMedNet has been able to ...
(Date:11/4/2015)... New York , November 4, 2015 ... to a new market report published by Transparency Market ... Share, Growth, Trends and Forecast 2015 - 2022", the global ... of US$ 30.3 bn by 2022. The market is ... the forecast period from 2015 to 2022. Rising security ...
Breaking Biology News(10 mins):